Tenpoint Therapeutics Ltd., a global, clinical-stage biotechnology company focused on developing treatments to rejuvenate vision in the aging eye, has appointed Carol Kearney as Chief Commercial Officer (CCO).

Kearney will spearhead Tenpoint’s commercial strategy, including preparation of the potential U.S. launch of BRIMOCHOL PF, an investigational, preservative-free, once-daily eye drop designed to address the loss of near vision.

“The appointment of Carol as our first Chief Commercial Officer is an important step forward in Tenpoint’s growth,” said Henric Bjarke, CEO of Tenpoint Therapeutics. “With her extensive experience in ophthalmology and her commercial leadership, I am confident in Carol’s ability to quickly scale up our commercial efforts and prepare for a successful launch of BRIMOCHOL PF. We look forward to building a world-class commercial team under her leadership.”

Experience

Kearney is an established commercialization executive with more than two decades of leadership experience in the biopharmaceutical industry, working with both private and publicly traded biotech companies.

Most recently, she served as Senior Vice President, Strategy Consulting at Lumanity, Inc., where she engaged with biopharmaceutical companies, business units and brands to define strategies to accelerate growth, overcome challenges and deliver results. During her tenure, Kearney led numerous engagements supporting clients to scale up their organizations and successfully launch new products into the marketplace.

Additionally, Kearney has a robust understanding of ophthalmology and optometry having previously worked in Global Marketing for Pfizer and Pharmacia, and in sales and marketing for Bausch & Lomb as well as for a broad range of ophthalmic companies developing products for conditions affecting both the anterior and posterior segments of the eye.

As Tenpoint’s CCO, she will lead the company’s global expansion from a clinical-stage entity to a market-leading commercial organization, with an immediate focus on the potential U.S. launch of BRIMOCHOL PF.

“I’m excited to join Tenpoint at this important and pivotal time in the company’s growth and development,” said Kearney. “Tenpoint’s innovative approach to presbyopia, and commitment to developing a pipeline targeting the largest areas of unmet need for rejuvenating vision in the aging eye is unparalleled. I look forward to collaborating with this talented and expanding team as well as industry leaders to deliver solutions that will significantly improve the quality of life for people living with presbyopia and other ophthalmic conditions.”